Diabetic osteopathy: Previously disputed but most likely important ailment;Diabetická osteopatie: Onemocnění kdysi sporné a pravděpodobně významné

Vnitrni Lekarstvi

Volumn 56, Issue 7, 2010, Pages 736-738

  Svačina, Štěpán ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antidiabetic drugs; Bone fracture; Diabetic osteopathy; Risk markers

Indexed keywords

COLLAGEN; ANTIDIABETIC AGENT;

BONE DENSITOMETRY; BONE DISEASE; DIABETIC OSTEOPATHY; DIABETIC PATIENT; DISEASE MARKER; FRACTURE; GLUCOSURIA; GLYCATION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; OSSIFICATION; PATHOGENESIS; QUANTITATIVE ANALYSIS; REVIEW; CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; METABOLIC BONE DISEASE; PATHOLOGIC FRACTURE;

BONE DISEASES, METABOLIC; DIABETES COMPLICATIONS; FRACTURES, SPONTANEOUS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 77956298608     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Vencovský J. Muskuloskeletální projevy u diabetes mellitus. In: Svačina Š et al (eds). Poruchy metabolismu a výživy. Praha: Galén 2010.
2. Sobotka L. Sarkopenie seniorů. In: Svačina Š et al (ed). Poruchy metabolismu a výživy. Praha: Galén 2010.
3. Isidro ML, Ruano B. Bone disease in diabetes. Curr Diabetes Rev 2010; 6: 144-155.
4. Schwartz AV. Diabetes Mellitus: Does it Affect Bone? Calcif Tissue lnt 2003; 73: 515-519.
5. Leidig-Bruckner G, Ziegler R. Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes 2001; 109 (Suppl 2): S493-S514.
6. Raska I Jr, Broulík P. The impact of diabetes mellitus on skeletal health: an established phenomenon with in established causes? Prague Med Rep 2005; 106: 137-148.
7. Amano A, Kawai S. Diabetes and oral osteoporosis. Clin Calcium 2007; 17: 186-191.
8. Lalla E, Lamster IB, Feit M et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000; 105: 1117-1124.
9. Won HY, Park JB, Park EY et al. Effect of hyperglycemia on apoptosis of notochordal cells and intervertebral disc degeneration in diabetic rats. J Neurosurg Spine 2009; 11: 741-748.
10. Li H, Jiang LS, Dai LY. High glucose potentiates collagen synthesis and bone morphogenetic protein-2-induced early osteoblast gene expression in rat spinal ligament cells. Endocrinology 2010; 151: 63-74.
11. Fantuzzi G, Mazzone TH. Adipose tissue in health and disease. Totowa: Humana Press 2007.
12. Haluzík M, Svačina Š. Metabolické jaderní receptory PPAR. Praha: Grada Publishing 2004.
13. Shockley KR, Lazarenko OP, Czernik PJ et al. PPARγ2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009; 106: 232-246.
14. Botushanov NP, Orbetzova MM. Bone mineral density and fracture risk in patients with type 1 and type 2 diabetes mellitus. Folia Med (Plovdiv) 2009; 51: 12-17.
15. Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin 2009; 25: 1057-1072.
16. Strotmeyer ES, Cauley JA, Schwartz AV et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005; 165: 1612-1617.
17. Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31: 845-851.
18. Palička V. Léky ovlivňující kostní metabolismus u diabetiků. Vnitř Lék 2009; 55: 368-370.
19. Svačina Š. Diabetes, antidiabetika a kost. Čas Lék čes 2010; 149: 282-284.
20. Gao Y, Li Y, Xue J et al. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol 2010; 635: 231-236.
21. Yamada C, Yamada Y, Tsukiyama K et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008; 149: 574-579.
22. Kimura T, Kuwata T, Ashimine S et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res 2010; 16: 121-129.
23. Matsumura M, Monden T, Nakatani Y et al. Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment. Med Princ Pract 2010; 19: 68-72.
24. Schulz TJ, Tseng YH. Emerging role of bone morphogenetic proteins in adipogenesis and energy metabolism. Cytokine Growth Factor Rev 2009; 20: 523-531.
25. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105-114.